American distribution agreement
Waters and Hitachi High Technologies America have entered into a distribution agreement allowing HTA to sell Waters? sample preparation and liquid chromatography (LC) columns to users in North America.
Waters and Hitachi High Technologies America have entered into a distribution agreement allowing HTA to sell Waters’ sample preparation and liquid chromatography (LC) columns to users in North America.“This agreement with HTA will expand the access of Waters industry-leading laboratory chemistry and consumable technologies to a broader user‑base that may not have had access previously,” said Mark Groudas, vice president Americas operation for the Waters division. “Waters invests significant resources to deliver advanced solutions that help laboratory scientists successfully address their most difficult and routine separation challenges.”“At HTA, we welcome the opportunity to offer our users additional applications and to extend the capabilities of our chromatography products through Waters’ chemistries,” said Kenji Osaki, VP/GM for the life sciences division of HTA.
According to the company, the sample preparation tools significantly enhance analyte signals and reduce unwanted noise by increasing sensitivity, reproducibility or throughput of LC–MS systems. Furthermore, the columns are reported to reduce time and cost per sample, while improving the quality of laboratory results.
For more information about these two companies visit www.hitachi-hta.com and www.waters.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
